Premium
Preliminary Study of Buprenorphine and Bupropion for Opioid‐Dependent Smokers
Author(s) -
Mooney Marc E.,
Poling James,
Gonzalez Gerardo,
Gonsai Kishor,
Kosten Thomas,
Sofuoglu Mehmet
Publication year - 2008
Publication title -
the american journal on addictions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.997
H-Index - 76
eISSN - 1521-0391
pISSN - 1055-0496
DOI - 10.1080/10550490802138814
Subject(s) - buprenorphine , abstinence , placebo , opioid , bupropion , medicine , addiction , anesthesia , opiate substitution treatment , psychiatry , smoking cessation , alternative medicine , pathology , receptor
In this double‐blind, placebo‐controlled trial, bupropion (BUPRO, 300 mg/day) was compared to placebo (PBO) for the concurrent treatment of opioid and tobacco addiction in 40 opioid‐dependent smokers stabilized on buprenorphine (BUPRE, 24 mg/day). Participants received contingent, monetary reinforcement for abstinence from smoking, illicit opioids, and cocaine. Significant differences in treatment retention were observed (BUPRE+BUPRO, 58%; BUPRE+PBO, 90%). BUPRO treatment was not more effective than placebo for abstinence from tobacco, opioids, or cocaine in BUPRE‐stabilized patients. These preliminary findings do not support the efficacy of BUPRO, in combination with BUPRE, for the concurrent treatment of opioid and tobacco addiction.